Eloxx Pharmaceuticals, Inc. reported its financial results for the third quarter ended September 30, 2026, and provided an update on its clinical development programs. On November 16, 2026, the company announced that it had dosed the first two patients in its global Phase 2b EXACT study of exaluren for nonsense mutation Alport syndrome.

The Phase 2b EXACT study (NCT07523581) is a randomized, placebo-controlled, delayed-start trial designed to enroll 24 patients with Alport syndrome caused by nonsense mutations in the COL4A3, COL4A4, or COL4A5 genes. The primary efficacy endpoint for the initial 16-week placebo-controlled portion is the change in podocyte foot process effacement, measured as the change in filtration slit density on kidney biopsies. The company expects to report topline data from this portion in mid-2027 and final 32-week data by the end of 2027.

In a separate development, Eloxx finalized the protocol for its Phase 2 EXPRESS study in nonsense mutation autosomal dominant polycystic kidney disease (ADPKD). The company received FDA clearance for the IND for this study on October 29, 2026. EXPRESS is a global, randomized, placebo-controlled trial designed for approximately 60 adults with genetically confirmed nonsense mutations in the PKD1 or PKD2 genes. The primary endpoint is the annualized rate of change in height-adjusted total kidney volume (htTKV). The company expects to dose the first patient in the third quarter of 2027 and report 52-week topline data in the first half of 2029.

On the leadership front, the company appointed T.R. Srinivas, M.D., as Senior Vice President and Chief Medical Officer in October 2026. Dr. Srinivas previously held U.S. Medical Affairs leadership responsibilities for ADPKD product development at Novartis. Additionally, the Board of Directors appointed Geno Germano as a director, effective October 19, 2026.

Financially, Eloxx reported research and development expenses of $4.0 million for the quarter ended September 30, 2026, compared to a net credit of $0.3 million for the same period in 2025. General and administrative expenses were $1.9 million for the third quarter of 2026, compared to $0.5 million in the prior year. The company reported a net loss of $5.5 million, or $(0.49) per share, for the three months ended September 30, 2026. As of September 30, 2026, the company had cash and cash equivalents of $56.3 million, compared to $62.0 million as of June 30, 2026. Eloxx stated that its cash and cash equivalents are sufficient to fund operations into 2028.